Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 do more quality enhancement research initiative (T2DM QUERI)

Diabetes Care

Volumn 33, Issue 12, 2010, Pages 2558-2560

  Teoh, Hwee ^a   Braga, Manoela F B ^b   Casanova, Amparo ^c   Drouin, Denis ^d   Goodman, Shaun G ^a,c,e   Harris, Stewart B ^f   Langer, Anatoly ^a,c,e   Tan, Mary K ^c   Ur, Ehud ^g   Yan, Andrew T ^a,c,e   Zinman, Bernard ^e,h   Leiter, Lawrence A ^a,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c CANADIAN HEART RESEARCH CENTRE   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f WESTERN UNIVERSITY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; HYPERGLYCEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; ASIAN; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HEALTH INSURANCE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL CARE; PREDICTION; PRIVATE HEALTH INSURANCE; PROSPECTIVE STUDY; PUBLIC HEALTH INSURANCE; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; RISK FACTORS;

EID: 79951710155     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0440     Document Type: Article

References (12)

1. Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA, Diabetes Registry to Improve Vascular Events (DRIVE) Investigators. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol 2010;26:297-302
2. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537
3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;32(Suppl. 1):S1-S152
4. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001;57:120-125 (Pubitemid 32200145)
5. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600-606
6. Ziemer DC, Miller CD, Rhee MK, Doyle JP, Watkins C Jr, Cook CB, Gallina DL, El-Kebbi IM, Barnes CS, Dunbar VG, Branch WT Jr, Phillips LS. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005;31:564-571 (Pubitemid 41187205)
7. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
9. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
10. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
11. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298
12. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139